Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Mallinckrodt
Baxter
Boehringer Ingelheim
Moodys

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Patent: 9,186,339

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,186,339
Title:Use of transcriptome modifying agents and chemotherapy or radiotherapy against cancer
Abstract: The use of transcriptome-modifying agents is disclosed in order to prevent malignant cells from undergoing the necessary genetic changes in order to combat cell insult and survive chemotherapy or radiotherapy. The combination of transcriptome-modifying agents comprises agents that inhibit the DNA methylation machinery plus a substance that inhibits histone deacetylation. A treatment kit is disclosed which includes an effective dose of hydralazine and valproic acid or a salt of same in the case of magnesium valproate, which is intended for use with radiotherapy or chemotherapy in the treatment of patients cancer.
Inventor(s): Gonzalez; Alfonso Duenas (Mexico D.F., MX), Flores; Luis Estrada (Col. Torielo Guerra, MX)
Assignee: UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (Mexico, C.P., Mexico City, unknown) PSICOFARMA, S.A. DE C.V. (Colonia Toriello Guerra, C.P., Mexico City, unknown)
Application Number:12/093,906
Patent Claims:see list of patent claims

Details for Patent 9,186,339

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2039-02-26
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Free Forever Trial 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2039-02-26
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2004-02-12 ⤷  Free Forever Trial 2039-02-26
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2007-03-28 ⤷  Free Forever Trial 2039-02-26
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Free Forever Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Harvard Business School
Johnson and Johnson
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.